Objective: No standard salvage chemotherapy regimen has been established for patients with advanced pancreatic cancer after failure of gemcitabine-based treatment. Although a Phase II study of S-1 monotherapy was conducted in patients with gemcitabine-refractory advanced pancreatic cancer, the number of patients enrolled was small. Methods: We retrospectively reviewed 84 consecutive patients who received S-1 monotherapy as a second-line treatment after gemcitabine failure at the Shizuoka Cancer Center between May 2004 and April 2008. The selection criteria in this study were age 20 -75 years, ECOG performance status 2 and preserved organ functions. S-1 was administered orally twice a day at a dose of 40 mg/m 2 for 28 days, followed by 14-day rest. Results: Fifty-two patients were selected for the analysis. Out of the 47/52 patients with measurable lesions, only 2 patients (4%) showed a partial response and 15 patients (32%) showed stable disease. The median progression-free survival was 2.1 months and the median overall survival was 5.8 months, with a 1-year survival rate of 12%. The common grade 3/4 toxicities were diarrhea (8%), anorexia (6%), fatigue (6%), anemia (6%) and leucopenia (4%). Conclusions: S-1 monotherapy is marginally effective and well tolerated in the second-line setting in patients with gemcitabine-refractory advanced pancreatic cancer.
INTRODUCTION
Pancreatic cancer is the fifth leading cause of cancer-related death, and the annual mortality is estimated to be more than 20 000 in Japan. The 5-year survival rate of pancreatic cancer is as low as 5.5%, and the poor prognosis is attributed to the difficulty in detection of the disease at an early stage, the high malignant potential and propensity of the cancer to metastasize, and the high resistance level to antitumor agents. Gemcitabine (GEM) showed superiority to 5-fluorouracil (5-FU) as first-line chemotherapy in patients with advanced pancreatic cancer (1) . Ever since, monotherapy with GEM has been the standard treatment for advanced pancreatic cancer. However, the median progression-free survival (PFS) time has been reported to be just 2 -4 months and the median overall survival time (MST) ranging from 4.9 to 8.2 months (2 -18) . To improve the prognosis of patients with advanced pancreatic cancer, numerous randomized controlled trials comparing GEM-based combination therapy with GEM monotherapy have been conducted, but only two regimens have shown any significant survival advantage; combined GEM plus capecitabine (13) and combined GEM plus erlotinib (18) . However, the efficacy of these regimens has also been only modest, with an MST of around 6 months. It can be said that these clinical trials of new agents in the first-line setting have not led to any remarkable progress in the treatment of pancreatic cancer.
Another possible way to improve the prognosis of patients with pancreatic cancer is the establishment of effective second-line chemotherapy. Until date, numerous Phase II trials have been conducted to evaluate the second-line chemotherapy after GEM failure in pancreatic cancer patients, and the median PFS time in these trials was 1.1 -5.5 months and the MST ranged from 2.9-8.3 months (19-38).
S-1 is an oral agent consisting of a mixture of tegafur, 5-chloro-2,4-dihydroxypyridine and potassium oxonate at a molar ratio of 1:0.4:1 (39) . In a Phase II study of S-1 for chemonaïve advanced pancreatic cancer, it was reported that 15 (37.5%) of 40 patients showed an objective response, including complete response in 1 patient, and the median PFS time and the MST were 3.7 and 9.2 months (40), respectively. On the basis of these results, S-1 was approved for the treatment of pancreatic cancer in Japan. Furthermore, a Phase II study of this agent in the second-line setting after GEM failure was performed in patients with metastatic pancreatic cancer; among the 40 patients enrolled in this study, the response rate was 16%, the median PFS time and MST were 2.0 and 4.5 months and 1-year survival rate was 14% (19) . The toxicity of S-1 was acceptable. Thus, S-1 has been used commonly as a second-line treatment in Japan.
However, this study may have some limitations such as the small number of patients enrolled and selection bias. We performed this retrospective survey because the efficacy and safety of S-1 monotherapy for patients with advanced pancreatic cancer in the second-line setting in clinical practice is still not well known.
PATIENTS AND METHODS

SUBJECTS
The subjects were 84 consecutive patients with advanced pancreatic cancer who received S-1 monotherapy between May 2004 and April 2008 as the second-line treatment after GEM failure, at the Shizuoka Cancer Center, and a retrospective review of their medical records was performed. In most of the patients, the diagnosis of pancreatic cancer was made by computed tomography (CT) and confirmed histologically by EUS-FNA, liver biopsy or cytological examination, where possible. The patient selection criteria for this retrospective study were age 20 -74 years, an Eastern Cooperative Oncology Group performance status (PS) of 0 -2, good bone marrow function (white blood cell count 3000/mm 3 , neutrophil count 1500/mm 3 , platelet count 100 000/mm 3 and hemoglobin 9.0 g/dl), renal function (serum creatinine 1.5 mg/dl) and liver function (total bilirubin 2.0 mg/dl and transaminase levels 2.5 times the upper limit of the respective normal ranges). Patients who had obstructive jaundice were eligible, but only after their serum transaminase levels decreased to within five times the upper normal limit of normal after biliary drainage. Patients who had not received GEM as part of their previous regimen, or with massive pleural effusion or ascites, active concomitant malignancy, brain metastasis, interstitial pneumonia or uncontrolled diabetes mellitus, or regularly using phenytoin, warfarin or frucitocin were excluded from the study. 2 BSA, 120 mg/day. S-1 was given for 28 days, followed by a rest period of 14 days. This treatment course was repeated until the appearance of disease progression or unacceptable toxicity, or until the patient no longer wished to continue the treatment.
EVALUATION
Tumor response was assessed by CT according to the Response Evaluation Criteria in Solid Tumors (RECIST, ver. 1.0). Primary pancreatic lesions were excluded from measurable lesions because of the difficulty in the precise measurement of their sizes. Toxicities were evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. PFS was counted from the date of treatment initiation to the date of documentation of disease progression or death, and overall survival was counted from the date of treatment initiation to the date of death or the last follow-up. PFS and overall survival curves were constructed using the Kaplan -Meier method.
RESULTS
SUBJECTS
Of the total of 84 patients registered, 52 were selected for this retrospective study according to the eligibility criteria. The reasons for exclusion of the remaining 32 patients were: age over 75 (10 patients); PS 3 (1 patient), inadequate organ functions (13 patients), massive effusion (2 patients), interstitial pneumonia (2 patients), active concomitant malignancy (3 patients) and regular use of warfarin (1 patient). The patient characteristics of the subjects are shown in Table 1 . Of the 52 patients, 29 (56%) were male, 40 (77%) had an ECOG PS of 0 -1 and the median age was 64.5 years (range: 42 -74). As for the prior treatment, nine patients had undergone curative surgery and received GEM treatment after recurrence. All the subjects had received prior GEM monotherapy, with a median course of GEM administrations of 4 (range: 2 -17); disease progression had been confirmed before the second-line therapy in all the subjects. Among the 51 patients who received GEM treatment at our hospital, 4 (7.8%) patients showed a partial response and 28 (55%) showed stable disease. At the start of the second-line chemotherapy, only 1 patient had a locally advanced pancreatic cancer, and 17 (33%) and 3 (6%) patients, respectively, had complicating ascites and pleural effusion.
TREATMENT COURSE
A total of 117 courses were administered, with a median of 2 courses per patient (range: 1 -10). Reduction of even the initial dose was required in two patients because of renal dysfunction. Dose reductions from the second course were 568 S-1 as second-line for pancreatic cancer required in nine patients (17%) and treatment was interrupted during the course in seven patients (13%) due to the development of anorexia, nausea, stomatitis, diarrhea, fatigue, vomiting, cholangitis or rash. S-1 monotherapy was discontinued in 45 patients (87%) because of disease progression and in 7 patients (13%) because of the development of non-hematological toxicities such as grade 3 diarrhea, anorexia or infectious colitis, and grade 2 infection and/or fatigue. The median dose intensity of S-1 was 311.2 mg/m 2 / week (range: 69.7-373.3).
TOXICITIES
The toxicities are summarized in Table 2 . No grade 4 toxicity was observed. Hematologic toxicities were generally mild; with grade 3 neutropenia observed in only one patient (1.9%) and grade 3 anemia in three (5.6%). The non-hematologic grade 3 toxicities were diarrhea (four patients, 8%), anorexia (three patients, 6%), fatigue (three patients, 6%), stomatitis (one patient, 2%), rash (one patient, 2%), infectious colitis (one patient, 2%), dehydration (one patient, 2%) and elevation of serum bilirubin (one patient, 2%). All of the adverse events were reversible.
EFFICACY
Forty-seven of all the patients had measurable lesions and were evaluable for response. A partial response was obtained in 2 patients (3.7%) and disease stabilization in 17 patients (31%). The median PFS time was 2.1 months (Fig. 1) , and the median survival time was 5.8 months, with a 1-year survival rate of 12% (Fig. 2) . In the subgroup analysis according to PS, the median survival time was 5.9 months in PS 0 -1 and 4.0 months in PS 2. As for tumor markers, the serum CA19-9 level was reduced to less than half in 9 (20%) of 44 evaluable patients.
DISCUSSION
In regard to the treatment for advanced pancreatic cancer after GEM failure in the second-line setting, it is difficult to compare Phase II trials, because of the varieties of patient backgrounds, such as the PS, the presence of metastatic or locally advanced lesion etc. After 32 of the total of 84 patients were excluded from this study, about a quarter of the subjects showed PS 2 and one-third had ascites. It would seem that the patient backgrounds were rather poor when compared with those in recent Phase II trials, although it is important to exercise caution while interpreting the results of this retrospective study. The response rate of 4% in this study appears to be inferior to that obtained in a previously conducted Phase II study of S-1 monotherapy, of 16%. As for the median PFS time, it was about 2 months in both this study and the previous Phase II study. The response rate and median PFS time following treatment with 5-FU plus celecoxib were 12.5% and 1.8 months, and those with capecitabine were 0% and 1.7 months, respectively. These results suggest the consistent efficacy of 5-FU derivatives in the second-line setting for pancreatic cancer. Furthermore, in a search of the PubMed database for trials of second-line therapy of pancreatic cancer patients after GEM failure, 20 studies met the following criteria: publication in journal, prospective trial and mentions of PFS or time to progression and MST. Among the 20 trials which evaluated various kinds of chemotherapeutic regimens, including combination chemotherapies, other than S-1 for pancreatic cancer after failure of GEM, the average response rate was 9.9 + 9.5%, and the average of median PFS time was 2.8 + 1.2 months. Thus, the response rates and PFS following treatment with S-1 in both this study and the previous Phase II study seem to be consistent with the values reported in these trials. As for the overall survival, the MST in this study and the previous Phase II study was 5.8 and 4.5 months, respectively, whereas the results of the aforementioned 20 trials indicated an average MST of 5.7 + 1.8 months. From these results, it is considered that S-1 has similar antitumor effects to other chemotherapy regimens, and that there has still been no success at establishing effective chemotherapy in the secondline setting after GEM failure in patients with pancreatic cancer.
As for the toxicities, similar results were obtained in this study and in the previous Phase II study of S-1. Since no grade 4 toxicities were observed and the treatment needed to be discontinued due to the appearance of toxicity(ies) in only seven patients (13%), it is suggested that the use S-1 may be feasible, in terms of its acceptable toxicity, in patients with pancreatic cancer in the second-line setting after GEM failure.
Although there are no established standard regimens for second-line chemotherapy of pancreatic cancer patients, the National Comprehensive Cancer Network guidelines currently recommend fluorinated pyrimidine-based therapy as the second-line chemotherapy after GEM failure in selected patients (41) . This study suggests that the use of S-1 may be considered as an option for the treatment of pancreatic cancer in the second-line setting, from the point of view of the efficacy and feasibility in Japan. Furthermore, some patients even with PS 2 can be candidates for the second-line chemotherapy with S-1 if they can take sufficient oral ingestion.
In 2005, a Phase III study compared an oxaliplatin/folinic acid/5-FU (OFF) regimen with best supportive care after confirming first-line GEM failure (42) . The study showed that OFF treatment prolonged the MST (the MST was 21 weeks in the treatment group vs. 10 weeks in the BSC group) and improved the overall survival time from the date of initiation of first-line therapy. At the 2008 ASCO annual meeting, the final results of a randomized Phase III study comparing OFF and FF in patients with GEM-refractory advanced pancreatic cancer were reported. A total of 168 patients were enrolled in this study and the results showed significantly improved survival with the OFF regimen than with the FF regimen (MST; 26 vs. 13 weeks, P ¼ 0.014) (43) . These results suggest that combined chemotherapy with oxaliplatin plus fluorinated pyrimidine therapy offers promise of becoming a new standard for the second-line treatment of pancreatic cancer after GEM failure.
In conclusion, S-1 monotherapy in the second-line setting is only marginally effective but well tolerated in patients with GEM-refractory advanced pancreatic cancer. Further development of second-line chemotherapies is warranted, and now a randomized clinical trial investigating the usefulness of a combined fluorinated pyrimidine, such as S-1, plus oxaliplatin is underway in Japan. 
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